Key Highlights

● Interpace filed an S-1 for a $20 million common stock offering underwritten solely by Lake Street Capital Markets.

● Closing is contingent on Interpace receiving conditional Nasdaq approval to uplist from its OTC listing.

● Net proceeds of about $17.8 million would fund Working Capital and new diagnostic test development.

● Two Private Equity funds control roughly 79% of the company before this offering closes.

Interpace Biosciences (OTC:IDXG) filed a Form S-1 on September 25, 2026 proposing a $20 million common stock offering underwritten solely by Lake Street Capital Markets, with the company saying it has applied to move its listing to the Nasdaq Capital Market under its existing ticker IDXG, up from its current over-the-counter listing, using the proceeds for working capital and new diagnostic test development.

The Offering and the Uplisting Condition

Lake Street Capital Markets, LLC is named as sole underwriter, with a 30-day option to buy an additional $3 million of shares to cover any over-allotment. Critically, the S-1 states that closing of the offering is contingent on Interpace receiving conditional approval from Nasdaq for the uplisting, meaning the deal and the exchange move are linked: if Nasdaq does not grant that approval, the offering as structured would not close as planned.

The company currently trades over the counter under IDXG, and temporarily traded as "IDXGD" for 20 trading days following a 1-for-5 Reverse Stock Split that became effective August 27, 2026 -- a split typically undertaken to raise a depressed share price toward levels an exchange like Nasdaq requires for listing. The temporary "D" suffix is a routine market convention used to flag a recently completed reverse split to traders before the ticker reverts to its normal form.

Use of Proceeds

Interpace expects net proceeds of about $17.8 million, or $20.6 million if Lake Street fully exercises its over-allotment option. The S-1 states the money will fund working capital, capital expenditures and general corporate purposes, and specifically flags potential Investment in new diagnostic tests, including tests for pancreatic cysts and Barrett's Esophagus, extending beyond the company's existing thyroid-cancer diagnostic franchise. Those two proposed test areas would represent an expansion of Interpace's molecular diagnostics menu beyond thyroid cancer and into gastrointestinal disease detection, an area it does not currently serve according to the filing.

The Business and Its Risk Factors

Interpace is a molecular diagnostics company focused on cancer risk assessment, built around products including ThyGeNEXT and ThyraMIR v2 for thyroid cancer evaluation, which the filing says demonstrate "99% NPV and a 94% PPV (30% disease prevalence)." The company previously offered a pancreatic cancer test, PancraGEN, but discontinued it after losing Medicare reimbursement on April 24, 2025, a reimbursement loss that speaks to the company's dependence on government and third-party payer coverage decisions.

The S-1's risk factors flag several vulnerabilities: uncertainty over whether the reverse split will keep the stock above Nasdaq's minimum bid-price requirement, potential further declines in trading liquidity, dilution for new investors at the offering's implied $2.01 per share price, heavy customer concentration around a single major partner (LabCorp), and the fact that two private equity funds control roughly 79% of the company before the offering and could sell substantial shares once any post-offering lockup expires. That concentration of ownership among two funds means public investors buying into the new offering would hold a comparatively small slice of the company relative to those existing controlling holders.

Milestones That Would Confirm the Plan

Watch for Nasdaq's decision on Interpace's uplisting application, since the offering's closing is expressly conditioned on receiving that conditional approval. Investors should also watch whether the stock's post-split trading price holds up well enough to satisfy exchange listing standards, and whether Lake Street exercises its over-allotment option, which would affect both the total proceeds raised and the resulting dilution to existing shareholders. The company's progress toward developing the pancreatic-cyst and Barrett's Esophagus tests referenced as a use of proceeds is another disclosure point to track in future filings.